Semorex Technologies

Company Overview

Snapshot

Founded in March 2002, Semorex Technologies operated with 1–10 employees, focusing on cancer therapeutics and diagnostics. The company secured two non-equity funding rounds, with the Office of the Chief Scientist participating in both, before ceasing operations in January 2019.

Business overview

Semorex Technologies specialized in the discovery and development of molecular compounds for anticancer therapies, targeting solid tumors and hematological malignancies. The company also developed a diagnostic approach for the rapid and reliable diagnosis of systemic/invasive fungal infections (SFI/IFI). Operating within the Health Tech & Life Sciences sector, Semorex focused on pharmaceuticals, healthcare providers, and life sciences, with its core technology centered on biological molecules for drug discovery and development.

Company Intelligence Q&A

What was Semorex Technologies' primary focus?

Semorex Technologies focused on discovering molecular compounds for potent and selective anticancer activity against solid tumors and hematological malignancies, and developing a diagnostic approach for systemic/invasive fungal infections.

When was Semorex Technologies founded?

Semorex Technologies was founded in March 2002.

What was the operational status of Semorex Technologies?

Semorex Technologies ceased to operate in January 2019.

Which organization participated in Semorex Technologies' non-equity funding rounds?

The Office of the Chief Scientist participated in non-equity funding rounds for Semorex Technologies in March 2015 and December 2015.

Where were Semorex Technologies' main offices located?

Semorex Technologies had an office in Jerusalem, Israel, and an additional office in Fanwood, New Jersey, USA.